Oisín Biotechnologies develops genetic medicines to address age-related diseases.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.07.2024 | Series A | $15M | - |
Mentions in press and media 7
| Date | Title | Description |
| 22.10.2024 | Этот учёный хочет постепенно заменить ваш мозг | Правительство США только что наняло учёного, который считает, что мы можем победить старение с помощью клонированных тел и обновлений мозга.
Американское агентство, занимающееся революционными разработками в области здравоохранения, наняло ... |
| 25.07.2024 | Oisín Biotechnologies Holds First Close of $15M Series A Financing | Oisín Biotechnologies, a Seattle, WA-based biotechnology company focused on mitigating the effects of age-related diseases, announced the first close of a $15M in Series A funding.
The round was led by AbbVie Ventures. Danjuma Quarless, Ph.... |
| 01.09.2022 | Seattle biotech company is the first to receive approval to test B cell gene therapy in humans | Immusoft’s steps to delivering a treatment using engineered B cells. (Screen grab from Immusoft’s website)
Seattle biotech startup Immusoft has received approval to begin clinical trials of its novel strategy for treating genetic disease, t... |
| 14.10.2021 | Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M | Immusoft CEO Sean Ainsworth. (Immusoft Photo)
Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system in a deal worth potentially more than $900 mill... |
| 27.05.2021 | Oisìn Biotechnologies Raises $5M in Seed Funding | Oisìn Biotechnologies, a Seattle WA-based company that specializes in mitigating the effects of age-related diseases, raised $5M in seed funding.
The round, which brought total funding to $9.5m, was led by Althea Group, LLC.
The company int... |
| 27.05.2021 | Oisín raises $5M to develop treatments for ‘zombie cells’ associated with age-related diseases | Two of Oisín’s three co-founders: CEO Matthew Scholz (left) and Chief Scientific Officer John Lewis. (Oisín Photos)
New funding: Seattle biotech startup Oisín Biotechnologies has raised a $5 million seed round. It’s currently developing pre... |
| - | Oisin Biotechnologies | “Oisín Biotechnologies” |
Reviews 0
